TELA Bio Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 3% revenue growth to $19.1M, driven by a 41% surge in international sales and 16% OviTex unit growth. The company launched OviTex LTR, expanded its field team, and reaffirmed 8%+ full-year revenue growth guidance, with strong momentum expected in the second half.
Fiscal Year 2025
-
Delivered 16% revenue growth in 2025 and record Q4 results amid major commercial restructuring, with strong European performance and new product launches. 2026 guidance is for at least 8% revenue growth, reflecting prudence as a large cohort of new sales reps ramps up.
-
Poised for mainstream adoption, the company is expanding its product portfolio and sales force, targeting at least 15% revenue growth next year. Financial efficiency is improving, with a strong capital position and new products set to drive further upside.
-
Q3 2025 revenue grew 9% year-over-year to $20.7 million, driven by strong adoption and international expansion. Net loss narrowed, salesforce efficiency improved, and guidance calls for at least 16% revenue growth in 2025 and 15% in 2026.
-
Hernia and reconstructive surgery markets are rapidly shifting to natural, non-permanent solutions, with robotic procedures and novel materials driving growth. The company is expanding its commercial team, optimizing sales strategies, and leveraging strong clinical data and unique contracting to accelerate revenue and market access. Financial discipline is expected to support profitability.
-
Q2 2025 revenue grew 26% year-over-year to $20.2 million, with strong gains in OviTex PRS and international markets. Gross margin improved, losses narrowed, and full-year guidance was reiterated, supported by new product launches, expanded clinical data, and a patient-centric sales strategy.
-
The company is expanding in hernia and plastic surgery markets with innovative, cost-effective products, gaining share as the industry shifts from traditional biomaterials. Stable gross margins, new leadership, and strong clinical data support growth, with profitability expected as revenue rises.
-
Q1 2025 revenue rose 12% year-over-year to $18.5 million, led by strong OviTex and European growth. Gross margin was 67.6%, with a 10% tariff expected to impact margins by up to 100 basis points starting Q2. 2025 revenue guidance of $85–88 million was reaffirmed.
Fiscal Year 2024
-
Q4 2024 saw modest revenue growth due to salesforce attrition and external headwinds, but full-year revenue rose 19% with strong product performance. Strategic salesforce rebuilding, new product launches, and a robust 2025 outlook position the company for accelerated growth.
-
A major market shift is underway as polypropylene mesh settlements drive hospitals toward alternative hernia repair solutions, with strong growth expected from new products and international expansion. Operational efficiencies and a recent capital raise support profitability targets for 2025.
-
Q3 2024 saw a 26% year-over-year revenue increase to $19 million, with strong growth in both U.S. and European markets and significant operational improvements. Full-year guidance was reaffirmed, and cost-saving measures plus a $43 million equity raise position the company for continued growth.
-
Revenue guidance remains strong despite Q2 disruptions, with robust growth in Europe and a complete hernia repair portfolio driving future expansion. Mass adoption of the IHR product and enhanced commercial execution are expected to accelerate profitability.
-
Q2 2024 revenue grew 11% year-over-year to $16.1 million despite ransomware-related disruptions, with strong OviTex adoption and European momentum. Full-year guidance of $74.5–$76.5 million is maintained, and sequential improvement is expected as new commercial initiatives ramp.